MedTrace Logo

Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

NCT06354465 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2024-04-09

No results posted yet for this study

Summary

This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders.

Conditions

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Lifespan

    lead OTHER

Principal Investigators

  • Justin Berk, MD · Lifespan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-07-01
Completion
2024-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06354465 on ClinicalTrials.gov